Join our “Ask the Ataxia Expert” session with Dr. Susan Perlman on May 12th at 11:30 AM CDT.  ADD TO CALENDAR

Blog

2021 NAF Funded Research

At NAF, we support researchers in many ways, including our grant process. Research grants allow Ataxia investigators to request funding for their studies. Lay summaries are available below for the research grants we funded in 2021.  $655,000 Funded Overall 13 Research Studies Funded Research Seed Money Grants Research Seed Money Read More…

Print Friendly, PDF & Email

NAF Welcomes Four New Board Members

Above: February 2021 Board of Directors Zoom Meeting NAF recently had a few changes to our Board of Directors. Joe DeCrescenzo, Mike Leader, and Bill Sweeney will be retiring after many years of dedicated service. We thank them for their time, commitment, and passion for the Ataxia community! We are Read More…

Print Friendly, PDF & Email

Coronavirus Precautions for Ataxia Patients

Last updated: February 2021 The coronavirus (COVID-19) pandemic is affecting communities worldwide. The health and safety of the Ataxia community is a priority at NAF. We have consulted with our Medical and Research Advisory Board, infectious disease specialists, the World Health Organization, and the Centers for Disease Control and Prevention (CDC) Read More…

Print Friendly, PDF & Email

NAF Joins Efforts with American Brain Coalition

NAF joined efforts spearheaded by the American Brain Coalition (ABC) to create a Neuroscience Center of Excellence at the FDA. We signed on to ABC’s letters to Congress. One letter asks Congresswoman DeGette and Congressman Upton to include the Neuroscience Center of Excellence in their Cures 2.0 legislation. The other letter urges Congressional Neuroscience Caucus co-chairs Read More…

Print Friendly, PDF & Email

NAF Supports FARA’s Call to Action

Friedreich’s Ataxia Research Alliance (FARA) is encouraging Reata Pharmaceuticals to submit a New Drug Application (NDA) for Omaveloxolone, which recently completed a Phase III clinical trial as a treatment for Friedreich’s Ataxia (FA). FARA is also urging the Food and Drug Administration (FDA) to consider approving the NDA. FARA has Read More…

Print Friendly, PDF & Email

Want to be a guest blogger?

Submit your name and blog topic. We’ll follow up with submission instructions.

Print Friendly, PDF & Email
Translate »